| Wissenschaftl. Titel | GUIDANCE – A multicenter phase II trial of maintenance durvalumab and olaparib after standard 1st line treatment (carboplatin or cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small cell lung cancer (SCLC) |
| Erkrankung |
Thorax:
Kleinzelliges Lungenkarzinom:
Erstlinie
|
| Kurzprotokoll | Kurzprotokoll |
erstellt 14.11.2024 Data entry III CCP
geändert 27.01.2025 Data entry IX CCP